Gabafast

Adjunctive therapy in partial seizures w/ & w/o secondary generalization in adults & childn >6 yr. Monotherapy in partial seizures w/ & w/o secondary generalization in adults & childn >12 yr. Peripheral neuropathic pain eg, painful diabetic neuropathy & post-herpetic neuralgia in adults.

Adult & adolescent ≥12 yr Initial titration: Day 1: 300 mg once daily. Day 2: 300 mg bid. Day 3: 300 mg tid. Epilepsy Adult & adolescent Follow initial titration schedule previously mentioned, or administer 300 mg tid on day 1. May be further increased in 300 mg daily increments every 2-3 days up to max of 3,600 mg daily. Childn ≥6 yr Initially 10-15 mg/kg daily, up-titrated over approx 3 days to reach effective dose of 25-35 mg/kg daily. Total daily dose should be divided in 3 single doses & max time interval between doses should not exceed 12 hr. Peripheral neuropathic pain Adult Follow initial titration schedule previously mentioned, or administer 900 mg daily as 3 equally divided doses. May be further increased in 300 mg daily increments every 2-3 days up to max of 3,600 mg daily. Patient w/ renal impairment CrCl ≥80 mL/min 900-3,600 mg daily, 50-79 mL/min 600-1,800 mg daily, 30-49 mL/min 300-900 mg daily, 15-29 mL/min 150-600 mg daily (150 mg to be administered as 300 mg every other day), <15 mL/min 150-300 mg daily (150 mg to be administered as 300 mg every other day). Total daily doses should be administered as 3 divided doses. Anuric patient undergoing haemodialysis Loading dose of 300-400 mg, then 200-300 mg following each 4-hr haemodialysis. Renally impaired patient undergoing haemodialysis 200-300 mg additional dose (in addition to maintenance dose) following each 4-hr haemodialysis.

May be taken with or without food: Swallow whole w/ sufficient fluid-intake eg, glass of water.

Hypersensitivity.

Discontinue use in case of signs or symptoms of hypersensitivity of unknown aetiology or anaphylaxis. Consider discontinuing use if acute pancreatitis develops. Risk of increased seizure frequency or onset of new types of seizures. Not effective against primary generalized seizures eg, absences. Abrupt w/drawal may precipitate status epilepticus in epileptic patients. Associated w/ dizziness & somnolence which could increase occurrence of accidental injury (fall). Associated w/ severe resp depression. Monitor for signs of suicidal ideation & behaviours. Carefully observe for signs of CNS depression (eg, somnolence, sedation & resp depression) in concomitant use w/ opioids. Carefully evaluate patients for history of drug abuse & observe for possible signs of abuse eg, drug-seeking behaviour, dose escalation, tolerance development. False +ve readings in semi-quantitative determination of total urine protein by dipstick tests. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May have minor or moderate influence on ability to drive & use machines. Reduced plasma clearance in elderly patients & patients w/ renal impairment. Not to be used during pregnancy & lactation unless benefits clearly outweigh the risks. Effects of long-term therapy on learning, intelligence, & development in childn & adolescents have not been adequately studied.

Viral infection; somnolence, dizziness, ataxia; fatigue, fever. Pneumonia, resp infection, UTI, infection, otitis media; leucopenia; anorexia, increased appetite; hostility, confusion & emotional lability, depression, anxiety, nervousness, abnormal thinking; convulsions, hyperkinesias, dysarthria, amnesia, tremor, insomnia, headache, sensations (eg, paresthesia, hyperaesthesia), abnormal coordination, nystagmus, increased, decreased, or absent reflexes; visual disturbances eg, amblyopia, diplopia; vertigo; HTN, vasodilatation; dyspnoea, bronchitis, pharyngitis, cough, rhinitis; vomiting, nausea, dental abnormalities, gingivitis, diarrhoea, abdominal pain, dyspepsia, constipation, dry mouth or throat, flatulence; facial oedema, purpura, rash, pruritus, acne; arthralgia, myalgia, back pain, twitching; impotence; peripheral oedema, abnormal gait, asthenia, pain, malaise, flu syndrome; decreased WBC, wt gain; accidental injury, fracture, abrasion.

Resp depression &/or sedation w/ opioids. Reduced bioavailability w/ Al & Mg-containing antacids.

Anticonvulsants

N02BF01 - gabapentin ; Belongs to the class of gabapentinoids. Used to relieve pain and other conditions.

Rx